Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma

Author:

Matsubara Nobuaki1ORCID,Yonese Junji2,Kojima Takahiro3,Azuma Haruhito4,Matsumoto Hiroaki5,Powles Thomas6,Rosenberg Jonathan E.7,Petrylak Daniel P.8,Matsangou Maria9,Wu Chunzhang9,Campbell Mary10,Yamashiro Mayumi11

Affiliation:

1. Department of Medical Oncology National Cancer Center Hospital East Chiba Japan

2. Department of Urology Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo Japan

3. Department of Urology Aichi Cancer Center Nagoya Aichi Japan

4. Department of Urology Osaka Medical and Pharmaceutical University Osaka Japan

5. Department of Urology Yamaguchi University, School of Medicine Ube Japan

6. Barts Cancer Institute, CRUK Experimental Cancer Medicine Centre London UK

7. Department of Medicine, Division of Solid Tumor Oncology Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center New York New York USA

8. Yale Cancer Center New Haven Connecticut USA

9. Astellas Pharma, Inc. Northbrook Illinois USA

10. Seagen Inc. Bothell Washington USA

11. Astellas Pharma, Inc. Tokyo Japan

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3